AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04446013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optic Nerve Sheath Diameter Measurement
Description: The change in intracranial pressure via optic nerve sheath diameter measurement
Study NCT02336568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytoine
Description: In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day
Study NCT02336568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day
Study NCT03636802 — intervention group
Intervention type: OTHER
Intervention: Questionnaire BPI
Description: Brief Pain Inventory (BPI) This is a scale of self-assessment, the Concise Pain Questionnaire in French. For all adult patients For any type of pain This is to ask the patient to answer questions in order to learn about us characteristics of his pain (its intensity and its repercussions on the plane biopsychosocial).
Study NCT00880854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG and CP-675,206
Description: Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15
Study NCT03002948 — intervention group
Intervention type: OTHER
Intervention: Orgasm
Description: clitoris volume, suprapubic angle, urethra-levator gap, suburethral triangle area measurement could made using 4 D transperineal ultrasonography. Clitoris fourchette distance, clitoris perineal body distance, clitoris urethra distance could made with special compasses.~Female Sexual Function Index orgasm domain score
Study NCT01531621 — intervention group
Intervention type: OTHER
Intervention: Biomarker sampling
Description: Blood samples every 8-12 weeks
Study NCT01599533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Study NCT04427202 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Referral to harm reduction services
Description: Participants are referred to harm reduction services
Study NCT02532621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous InterGraft Connector
Description: The device is designed for transcatheter delivery within a vein and connection to an AVG that has been tunneled under the skin in a standard manner. The connection is made via a small skin incision.
Study NCT02532621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sutured arterial anastomosis of an implanted vascular graft for hemodialysis
Description: The arterial anastomosis of the implanted vascular graft for hemodialysis is formed using standard suturing technique.
Study NCT02532621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemodialysis
Description: The implanted vascular graft is intended as a vascular access for performing hemodialysis treatments.
Study NCT01566539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (OT) 24 IU
Description: Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.
Study NCT03291977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescéine Sodique Faure
Description: Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.
Study NCT03291977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: White-light surgery
Description: The surgery will be performed under classical conditions
Study NCT03108105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AOS-C2001-B
Description: A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
Study NCT01566539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Vasopressin (AVP)
Description: Participants will self-administer a 1 ml solution containing 20 units of AVP. Five puffs per nostril, each with 2 International Units (IU) AVP. Ten puffs total).
Study NCT01566539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
Study NCT01566539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
Study NCT06693076 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Description: The intervention in this study is urgent, not elective. The conditions for the surgery are therefore different: any time of day, the surgeon on shift, the state of the patients.
Study NCT00748358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
Study NCT01505465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
Study NCT01505465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
Study NCT02355548 — intervention group
Intervention type: OTHER
Intervention: Outpatient Treatment of Pulmonary Embolism
Description: Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized.
Study NCT01873768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: 1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.
Study NCT01873768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ε-Aminocaproic Acid (EACA)
Description: 7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
Study NCT03001609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010
Description: Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi\[14C\]
Study NCT04935827 — intervention group
Intervention type: OTHER
Intervention: Season of Year
Description: We stratify patients into 4 groups based on the season of the year (between 12/1/2007-11/30/2017)~* Winter: December, January, February~* Spring: March, April, May~* Summer: June, July, August~* Fall: September, October, November
Study NCT04935827 — intervention group
Intervention type: OTHER
Intervention: Hospitalized 14 days prior to dialysis
Description: We further stratify patients into 3 groups based on whether they were hospitalized within 14 days prior to dialysis~* Group 1: No hospitalization prior to dialysis~* Group 2: Hospitalized within 14 days prior to dialysis for an acute infectious respiratory condition or one of the following acute cardiac conditions (arrhythmia, myocardial infarction, stroke, or fluid overload)~* Group 3: Hospitalized within 14 days prior to dialysis for a condition not in Group 2
Study NCT00514995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: 4.5 g/night - 9 g/night, liquid taken twice per night
Study NCT04275947 — intervention group
Intervention type: OTHER
Intervention: nCapp, a cell phone-based auto-diagnosis system
Description: Combined with 15 questions online, and a predicated formula to auto-diagnosis of the risk of COVID-19
Study NCT02504034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transhepatic portosystemic shunt
Description: Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.
Study NCT02504034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6-French sheath
Study NCT02504034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22-gauge chiba needle
Study NCT02504034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 260-cm-long stiff shaft wire
Study NCT01566539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Vasopressin (AVP) 40 IU
Description: Participants will self-administer a 0.5 ml solution containing 40 international units (IU) of AVP. 5 puffs in total, each with 4 International Units (IU) AVP.
Study NCT01566539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Subjects will take 1.0 mg of lorazepam orally 60 minutes prior to fMRI scan.
Study NCT01213732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolated inferior limb perfusion
Description: Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
Study NCT03424057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Asymmetric Primary Closure and Additional Skin Excision Technique
Description: In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume.
Study NCT02504034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon catheter
Study NCT02504034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bare metal stent
Study NCT02504034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covered stent
Study NCT02282917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-42
Description: AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
Study NCT01001637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin Formulation
Description: 2000mg or 3000mg daily BID
Study NCT01001637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00794911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Therapy
Description: 8 weekly individual counseling sessions
Study NCT00497367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) TAXUS Petal
Description: TAXUS Petal, paclitaxel eluting stent
Study NCT02581800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App group
Study NCT02363751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab).~In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15 mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up.
Study NCT01129999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: a cognitive-behavioral smoking cessation program; 6, weekly-held, group sessions (90 min each)
Study NCT01129999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: hypnotherapeutic smoking cessation program; 6, weekly-held, group sessions (90 min each)
Study NCT03184454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept Deep Brain Stimulation
Description: Deep Brain stimulation involves bilateral stereotactic placement of stimulating leads into specific brain structures. Leads are attached to permanent subcutaneous wires and battery-powered implantable neurostimulators (INSs). Noninvasive INS programming can achieve a balance between maximal benefit (reduction in disabling OCD symptoms), while minimizing adverse effects (eg sensorimotor effects such as dysarthria or paresthesias; as well as behavioral side effects, e.g., hypomania, insomnia, or increased anxiety).
Study NCT03331965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide 5 MG/ML Injectable Solution
Description: A one-time dose of promotility agent (metoclopramide 10 mg in 10 mL saline IV) will be administered at the time of GJ placement.
Study NCT03331965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement.
Study NCT00794911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: 8 weekly individual counseling sessions
Study NCT03027336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coleosoma
Description: patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.
Study NCT03027336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will take one tablet daily for 12 weeks.
Study NCT01171885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 20 ml of 0.9% saline
Study NCT01171885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20 ml of Ropivacaine 0.25%.
Study NCT03338465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duolith SD1, STORZ Medical, Switzerland with F-SW applicator
Description: The procedure will be performed with the patient in lateral positioning of the decubitus. The treatment area will be prepared with a coupling ultrasound gel to minimize the loss of shockwave energy at the interface between the tip of the applicator and the skin. The inline ultrasonic guide will be used to concentrate the shockwaves on the pain area in the trochanteric region. No local anesthesia will be applied.
Study NCT02809092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cells + Chemotherapy Starting
Description: Drug: G-CSF G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.~Other Names:~Filgrastim Neupogen Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Fludarabine Phosphate Fludara Drug: Cytarabine 2 g/m\^2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Procedure: Natural Killer (NK) Cell Infusion NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema.
Study NCT02254733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Description: CBSST integrates CBT and SST techniques and neurocognitive compensatory aids. The treatment manual includes a patient workbook that describes the skills and includes homework assignment forms. Cognitive therapy is combined with role play practice of communication skills and problem-solving training. The ACT-adapted, team-delivered individual CBSST intervention will be delivered in 3 6-session modules (Cognitive Skills, Social Skills, and Problem Solving Skills) for a total of 18 weekly individual therapy sessions, but with participants completing the sequence of 3 modules twice, for a total of 36 sessions (9 months).
Study NCT03424057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Karydakis technique.
Description: In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method
Study NCT02254733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assertive Community Treatment (ACT)
Description: Assertive Community Treatment model is a evidence based practice model. ACT teams are multi-disciplinary and provide comprehensive services to individuals in their natural setting with small staff to recipient ratio. ACT teams use assertive engagement to proactively engage individuals in treatment providing services and support directly to individuals that are tailored to meet their specific goals and needs.
Study NCT04120168 — intervention group
Intervention type: GENETIC
Intervention: Laboratory Tests
Description: * Acid Alpha IgGlucosidase alpha enzyme test for Late Onset Pompe Disease and gene sequencing test from the same sample in samples with low enzyme activity~* Genetic Analysis for DMD (only in boys): Detection of dystrophin gene for duplication and deletion with MLPA (Multiplex-ligation dependent probe amplification) and re-screening for other mutations by gene sequencing in patients without MLPA deletion / duplication.
Study NCT01171885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20 ml of Ropivacaine 0.5%.
Study NCT02183558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OGTT by randomization
Study NCT02183558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OGTT by indication
Study NCT03807479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: 2 film-coated tablets à 15mg for oral administration on a daily basis
Study NCT00728260 — intervention group
Intervention type: BIOLOGICAL
Intervention: None administered in this study
Description: N/A in this study
Study NCT03273413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy
Study NCT03273413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive tablet
Study NCT03850470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: clinical examination
Description: Thorough examination including history, screening, motion testing, strength testing, special testing
Study NCT03850470 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Low field MRI .25 Tesla
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered orally.
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered orally.
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Administered orally.
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Administered orally.
Study NCT03141359 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Primary tumor SBRT
Study NCT03141359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: concurrent chemotherapy
Study NCT03141359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: concurrent chemotherapy
Study NCT03141359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis Platinum
Description: concurrent chemotherapy
Study NCT03141359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: concurrent chemotherapy
Study NCT03141359 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: mediastinal radiation
Study NCT03141359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: adjuvant immunotherapy
Study NCT04466241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet
Description: 2 tablets morning and evening from Day 1 to Day 10
Study NCT04466241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet
Description: 2 tablets morning and evening from Day 1 to Day 10
Study NCT00745251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: 15 mg Phentermine and 92 mg Topiramate
Study NCT00745251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00924066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixempra (Ixabepilone (BMS-247550) )
Description: Participants received Ixabepilone 6mg/m\^2 for a total of 30mg/m\^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
Study NCT04466241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 40Mg Oral Tablet
Description: 1 tablet daily from Day 1 to Day 10